CASP3 and lung cancer: Inhalable liposomamV MMADr primary lung cancer demonstrated high lung distribution, rapid absorption, 2.36-fold higher bioavailability vs. oral, significant tumor reduction, apoptosis induction (Caspase-3, TUNEL), P-Akt suppression, inflammation attenuation (↓ TNF-α, W/D ratio); tested in primary lung cancer rat model.